Association of ACE2 Gene Variants with the Severity of COVID-19 Disease-A Prospective Observational Study.
SARS-CoV-2
angiotensin receptors
coronavirus
gene polymorphism
single nucleotide polymorphism
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
02 10 2022
02 10 2022
Historique:
received:
18
08
2022
revised:
23
09
2022
accepted:
29
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2), has triggered an enormous scientific response. Many studies have focused on understanding the entry of the SARS-CoV-2 virus into the host cell. The angiotensin-converting enzyme-2 (ACE2) is recognized as the host receptor used by SARS-CoV-2 to enter its target cells. Recent studies suggest that ACE2 gene polymorphisms might be candidates for genetic susceptibility to SARS-CoV-2 infection. The aim of this study is to evaluate the influence of ACE2 polymorphisms on COVID-19 disease risk and severity. In our study, we confirmed that there is a statistically significant increased risk of a more severe disease course of SARS-CoV-2 infection associated with the need for hospitalization in intensive care for patients with specific polymorphisms of the ACE2 gene. The most significant correlation was found for variant ACE2 rs2285666 (AA allele, OR = 2.12,
Identifiants
pubmed: 36231922
pii: ijerph191912622
doi: 10.3390/ijerph191912622
pmc: PMC9564490
pii:
doi:
Substances chimiques
Angiotensins
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Pharmgenomics Pers Med. 2021 May 27;14:621-629
pubmed: 34079337
Medicine (Baltimore). 2018 Oct;97(42):e12917
pubmed: 30335025
Life Sci. 2019 May 15;225:39-45
pubmed: 30917908
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Int J Pept. 2012;2012:256294
pubmed: 22536270
Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2281-90
pubmed: 16055515
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
J Biol Chem. 2000 Oct 27;275(43):33238-43
pubmed: 10924499
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Clin Interv Aging. 2020 Jul 21;15:1231-1240
pubmed: 32764907
Lung. 2020 Dec;198(6):867-877
pubmed: 33170317
Microbiol Mol Biol Rev. 2005 Dec;69(4):635-64
pubmed: 16339739
Cardiovasc Diabetol. 2018 Sep 18;17(1):127
pubmed: 30227878
EClinicalMedicine. 2020 Dec;29:100630
pubmed: 33200120
Lipids Health Dis. 2018 Oct 20;17(1):241
pubmed: 30342552
J Clin Microbiol. 2010 Aug;48(8):2940-7
pubmed: 20554810
Viruses. 2021 Jun 05;13(6):
pubmed: 34198852
Genes (Basel). 2020 Sep 03;11(9):
pubmed: 32899439
Am J Hypertens. 2021 Apr 20;34(4):367-376
pubmed: 33386398
Infect Dis Clin North Am. 2019 Dec;33(4):869-889
pubmed: 31668196
Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4956-4961
pubmed: 30070331
J Mol Med (Berl). 2006 Jan;84(1):88-96
pubmed: 16283142
Mayo Clin Proc. 2020 Jun;95(6):1222-1230
pubmed: 32376099
Front Cardiovasc Med. 2020 Apr 23;7:71
pubmed: 32391384
Pharmacogenet Genomics. 2021 Oct 1;31(8):165-171
pubmed: 34001841
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Gene. 2020 Dec 15;762:145102
pubmed: 32882331
Front Med (Lausanne). 2020 Oct 30;7:582793
pubmed: 33195331
Br J Pharmacol. 1998 Nov;125(5):1028-32
pubmed: 9846641
Mol Genet Genomic Med. 2021 Jun;9(6):e1672
pubmed: 33818000
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Front Physiol. 2014 Jun 24;5:227
pubmed: 25009501
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904